Evidence map›Paper›PMID 28808912›Full record

ReviewCurrent neurology and neuroscience reports2017

Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias.

Nicolaas I Bohnen, Martijn L T M Müller, Kirk A Frey

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current neurology and neuroscience reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. A case report: Neuroimaging in an atypical presentation of Parkinson's disease.The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Molecular Imaging for Early-Stage Disease Diagnosis.Advances in experimental medicine and biology · 2023
    Article
  9. Morphological basis of Parkinson disease-associated cognitive impairment: an update.Journal of neural transmission (Vienna, Austria : 1996) · 2022
    Review
  10. Cortical thinning in dementia with Lewy bodies and Parkinson disease dementia.The Australian and New Zealand journal of psychiatry · 2020
    Article
  11. Topography of Cholinergic Changes in Dementia With Lewy Bodies and Key Neural Network Hubs.The Journal of neuropsychiatry and clinical neurosciences · 2020
    Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Nicolaas I BohnenDepartments of Radiology and Neurology, University of Michigan, and Neurology service and GRECC, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA. nbohnen@umich.edu.
Martijn L T M MüllerDepartments of Radiology and Neurology, University of Michigan, and Neurology service and GRECC, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA.
Kirk A FreyDepartments of Radiology and Neurology, University of Michigan, and Neurology service and GRECC, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA.
University of Michigan–Ann Arbor · US

Funding

Tomography and Data AnalysisP01NS015655 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GILMAN, SID · 1985 to 2012
$13.0M
Public Outreach and Education CoreP50NS091856 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ALBIN, ROGER L · 2014 to 2019
$10.1M
Hyposmia, Cholinergic Denervation and Incipient Cognitive Decline in PDR01NS070856 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BOHNEN, NICOLAAS IDA · 2010 to 2014
$1.9M
IMAGING BIOMARKERS OF PROGRESSION OF MOBILITY IMPAIRMENT IN PDI01RX000317 · VA · VETERANS HEALTH ADMINISTRATION · PI BOHNEN, NICOLAAS IDA · 2012 to 2014
–
NINDS NIH HHS P01 NS015655NINDS NIH HHS P50 NS091856NINDS NIH HHS R01 NS070856RRD VA I01 RX000317
6 · The paper itself

Abstract

purpose of reviewThe aims of the study were to review recent advances in molecular imaging in the Lewy body dementias (LBD) and determine if these may support the clinical but contested temporal profile distinction between Parkinson disease (PD) with dementia (PDD) versus dementia with Lewy bodies (DLB). RECENT

findingsThere do not appear to be major regional cerebral metabolic or neurotransmitter distinctions between PDD and DLB. However, recent studies highlight the relative discriminating roles of Alzheimer proteinopathies. PDD patients have lower cortical β-amyloid deposition than DLB. Preliminary tau PET studies suggest a gradient of increasing tau binding from cognitively normal PD (absent to lowest) to cognitively impaired PD (low) to DLB (intermediate) to Alzheimer disease (AD; highest). However, tau binding in DLB, including the medial temporal lobe, is substantially lower than in AD. Alzheimer-type proteinopathies appear to be more common in DLB compared to PDD with relative but no absolute differences. Given the spectrum of overlapping pathologies, future α-synuclein ligands are expected to have the best potential to distinguish the LBD from pure AD.

Indexed as

DementiaHumansLewy Body DiseaseMolecular ImagingParkinson Diseasetau ProteinsTemporal Lobetau ProteinsAcetylcholineDementia with Lewy bodiesDiagnostic criteriaDopamineParkinson disease with dementiaβ-Amyloid

Identifiers

PMID28808912
PMCPMC5873980
OpenAlexW2749274031

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.